Primary biliary cirrhosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 4: Line 4:
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}


{{PleaseHelp}}
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


==Overview==
OR


==Natural History, Complications and Prognosis==
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
===Natural History===
Stages of primary biliary cirrhosis are as follows:
*Stage 1 - Portal Stage: Normal sized triads; portal inflammation, subtle [[bile duct]] damage.  [[Granuloma]]s are often detected in this stage.


*Stage 2 - Periportal Stage: Enlarged triads; periportal [[fibrosis]] and/or [[inflammation]]. Typically characterized by the finding of a proliferation of small bile ducts.
OR


*Stage 3 - Septal Stage: Active and/or passive fibrous [[septa]].
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==


*Stage 4 - Biliary Cirrhosis: Nodules present; garland or jigsaw pattern.
===Natural History===
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


===Complications===
===Complications===
Patients with primary biliary cirrhosis have an increased risk of [[hepatocellular carcinoma]].
*Common complications of [disease name] include:
**[complication 1]
**[complication 2]
**[complication 3]


===Prognosis===
===Prognosis===
The serum [[bilirubin]] level is an indicator of the prognosis of primary biliary cirrhosis, with levels of 2–6&nbsp;mg/dL having a mean [[survival time]] of 4.1 years, 6–10&nbsp;mg/dL having 2.1 years and those above 10&nbsp;mg/dL having a mean survival time of 1.4 years.<ref>[http://emedicine.medscape.com/article/171117-followup eMedicine > Primary Biliary Cirrhosis: Follow-up] Author: Nikolaos T Pyrsopoulos. Coauthor: K Rajender Reddy. Updated: Dec 23, 2009</ref>
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
 
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
[[Anti-nuclear antibodies]] appear to be prognostic agents in PBC. [[Anti-glycoprotein-210 antibodies]], and to a lessor degree [[anti-p62 antibodies]] correlate with progression toward end stage liver failure. [[Anti-centromere antibodies]] correlate with developing portal hypertension.<ref name="pmid17187436">{{cite journal | author = Nakamura M, Kondo H, Mori T, et al | title = Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis | journal = Hepatology | volume = 45 | issue = 1 | pages = 118-27 | year = 2007 | pmid = 17187436 | doi = 10.1002/hep.21472}}</ref> Anti-np62<ref name="pmid11303304">{{cite journal | author = Nesher G, Margalit R, Ashkenazi YJ | title = Anti-nuclear envelope antibodies: Clinical associations | journal = Semin. Arthritis Rheum. | volume = 30 | issue = 5 | pages = 313-20 | year = 2001 | pmid = 11303304 | doi = 10.1053/sarh.2001.20266}}</ref> and anti-sp100 are also found in association with PBC.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
 
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
After liver transplant, the recurrence rate may be as high as 18% at 5 years, and up to 30% at 10 years. There is no consensus on risk factors for recurrence of the disease.<ref name="k&c-p429">Killenberg & Clavien (2006), p.&nbsp;429.</ref>
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.


==References==
==References==
{{reflist|2}}
{{Reflist|2}}
 
[[Category:Gastroenterology]]
[[Category:Hepatology]]
[[Category:Disease]]
[[Category:Needs overview]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 21:19, 11 August 2017

Primary Biliary Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Primary Biliary Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary biliary cirrhosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary biliary cirrhosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary biliary cirrhosis natural history, complications and prognosis

CDC on Primary biliary cirrhosis natural history, complications and prognosis

Primary biliary cirrhosis natural history, complications and prognosis in the news

Blogs on Primary biliary cirrhosis natural history, complications and prognosis

Directions to Hospitals Treating Primary biliary cirrhosis

Risk calculators and risk factors for Primary biliary cirrhosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Natural History, Complications, and Prognosis

Natural History

  • The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
  • The symptoms of (disease name) typically develop ___ years after exposure to ___.
  • If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

Complications

  • Common complications of [disease name] include:
    • [complication 1]
    • [complication 2]
    • [complication 3]

Prognosis

  • Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
  • Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
  • The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
  • [Subtype of disease/malignancy] is associated with the most favorable prognosis.
  • The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Primary_biliary_cirrhosis_natural_history,_complications_and_prognosis&oldid=1340143"